Ecallantide

Ecallantide
Clinical data
Trade names	Kalbitor
Other names	DX-88
AHFS/Drugs.com	Monograph
License data	US DailyMed: Ecallantide; US FDA: Ecallantide;
Routes of; administration	Subcutaneous injection
ATC code	B06AC03 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Elimination half-life	1.5–2.5 hours
Excretion	Kidney
Identifiers
	IUPAC name [Glu20,Ala21,Arg36,Ala38,His39,Pro40,Trp42]tissue factor pathway inhibitor (human)-(20-79)-peptide (modified on reactive bond region Kunitz inhibitor 1 domain containing fragment);
CAS Number	460738-38-9 ;
PubChem CID	118984459;
IUPHAR/BPS	6955;
DrugBank	DB05311 ;
ChemSpider	34983390 ;
UNII	5Q6TZN2HNM;
ChEMBL	ChEMBL1201837 ;
CompTox Dashboard (EPA)	DTXSID90196709 ;
Chemical and physical data
Formula	C305H442N88O91S8
Molar mass	7053.90 g·mol−1
	(what is this?) (verify)

Ecallantide (trade name Kalbitor) is a drug used for the treatment of hereditary angioedema (HAE) and in the prevention of blood loss in cardiothoracic surgery.^[1] It is an inhibitor of the protein kallikrein and a 60-amino acid polypeptide which was developed from a Kunitz domain through phage display to mimic antibodies inhibiting kallikrein.^[1]

^ ^a ^b Lehmann A (August 2008). "Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery". Expert Opinion on Biological Therapy. 8 (8): 1187–99. doi:10.1517/14712598.8.8.1187. PMID 18613770. S2CID 72623604.